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Abstract
Background: The present preliminary study describes concentration time courses of the NSAID carprofen in the
plasma and synovial fluid in a microfrature sheep model after transcutaneous treatments with a novel application
device (Vetdrop®). To treat circumscribed inflammatory processes a transcutaneous application device could
potentially be beneficial. After transcutaneous application normally lower systemic concentrations are measured
which may reduce the incidence of side effects, whereas efficacy is still maintained.
In this study carprofen was used based on its capacity to provide analgesia after orthopaedic procedures in sheep
and it is considered that it may have a positive influence on the healing of cartilage in low concentrations.
Results: In all transcutaneously treated animals, carprofen plasma concentrations exceeded those of synovial fluid,
although plasma levels remained significantly reduced (300-fold) as compared to carprofen administered
intravenously. Furthermore, in contrast to the intravenously treated animals, a modest accumulation of carprofen in
plasma and synovial fluid was observed in the transcutaneously treated animals over the 6-week treatment period.
Conclusions: The transcutaneously administered carprofen using the Vetdrop® device penetrated the skin and
both, plasma- and synovial concentrations could be measured repeatedly over time. This novel device may be
considered a valuable transcutaneous drug delivery system.
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Background
Nonsteroidal anti-inflammatory drugs (NSAID’s) are com-
monly used in human and veterinary medicine to treat
inflammatory processes and to relieve mild to moderate
pain. Most NSAIDs inhibit the activity of the cyclooxy-
genase enzymes (COX1 and COX2), which produce
prostaglandins. Prostaglandins are important factors for
the pathogenesis of inflammation, swelling, pain and
fever [1-3]. These prostaglandins also fulfil various
physiological functions, such as mucosal defence through
prevention and promotion of healing of mucosal erosions.
The administration of NSAID’s can be accompanied by
miscellaneous side effects, ranging from gastrointestinal
mucosal damage, aplastic anaemia, and inhibition of
thrombocyte aggregation to increased cardiovascular
risks and renal failure [4-7]. Transcutaneous application
of NSAID’s could potentially be beneficial when treating
circumscribed inflammatory processes, due to the fact that
systemic concentrations of the drugs are lower, thereby
reducing the incidence of side effects. This concept is
supported by findings from previous studies where the
topical application of NSAID’s led to lower plasma
levels as compared to systemic administration, whilst
still maintaining efficacy [8-10].
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The skin constitutes a barrier for nocive influences
and therapeutic agents. Therefore, much effort has been
invested into overcoming this barrier for therapeutic
purposes. As such, the development of carriers to aid in
the transport of therapeutic compounds across such bar-
riers represents a possible way of skin penetration [11].
MedDrop Technology AG (Thundorf, Switzerland) has
developed a treatment system (Vetdrop®) employing car-
riers for transcutaneous application of pharmaceutical
agents, including the NSAID carprofen.
Carprofen was used in this study based on its capacity
to provide analgesia after orthopaedic procedures [12,13]
in sheep. In addition, carprofen may have a positive
influence on the healing of cartilage in low concentrations
[14]. Benton et al. [15] showed in an in vitro study that
the administration of 1 and 10 μg/ml carprofen resulted
in significantly higher glycosaminoglycan synthesis and
cartilage matrix production, whereas a concentration of
20 μg/ml carprofen blocked this effect.
The current study was based on the hypothesis that the
Vetdrop® Technology would allow the transcutaneous
transport of carprofen into the stifle joint, which should
be measureable in synovial fluid samples after application.
Methods
The study was conducted according to the Swiss legal
requirements for animal protection and welfare (TschG
455) and received ethical approval by the federal veterinary
authorities ‘Kantonale Tierversuchskommission Zürich’
(permission No 193/2009). It was part of a larger-scale
project published and described elsewhere [16]. In brief,
28 sheep with a mean age of 2.5 ± 0.5 years and a body
weight average of 59.4 ± 10.2 kg underwent microfracture
surgery on the medial condyle either on the left or right
stifle joint.
The animals were allocated to 6 different treatment
groups. Groups 1 – 5 were treated using the Vetdrop®
system and group 6 received carprofen intravenously.
The transcutaneous treatment system (Vetdrop®) was
developed for the transcutaneous application of pharma-
ceutical substances. The system consists of an oxygen
generator and an application system, which is used in
conjunction with specially developed vehicle solutions.
The oxygen generator extracts oxygen from the atmos-
phere and this highly concentrated oxygen serves as a
propellant. The oxygen is first stored in a pressure con-
tainer and during treatment, the oxygen flows through
a pressure reducing valve and a treatment tube to the
application device.
The applicator serves as a nano-dispersion-device con-
sisting of a drug reservoir, which lies within a gas tank.
The pharmaceutical ingredients are filled into the drug
reservoir through a port, surrounded by the oxygen gas
tank. The oxygen combines with carrier substance under
pressure and propels it through the diffuser. The dif-
fuser assembly utilizes the Venturi-Effect (fluid pressure
Figure 1 Treatment procedure. A. The applicator was held in a 90° angle to the application site. B. An area of approximately 10 cm2 was
treated. C. Treatment area.
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decreases in response to a constricted area of flow), in
order to disperse the carrier. The size of the droplets
lies in the range of nanometers. The size is regulated
via a needle lace, which alters the width of the port.
The employed carriers are a proprietary product of
Arvine Pharma AG (MedVital Serum, Arvine Pharma
AG, Thundorf Switzerland). The vehicles are based on
oil-in-water or water-in-oil carriers. The active ingredients
are incorporated in water and oil phases.
Group 1 (VE) was treated with only vehicle, group 2
(VECH) with vehicle and chito-oliogosaccharids (2%),
group 3 (VECA) with vehicle and carprofen (5.6%, total
dose 0.5 – 0.6 mg/kg), group 4 (VECHCA) with vehicle,
chito-oligosaccharids (2%) and carprofen (6.7 ± 15%, total
dose 0.5 – 0.6 mg/kg), group 5 (S) was transcutaneously
sham treated and group 6 (CA) was intravenously treated
with carprofen (5%). This group received once per day
4 mg/kg BW carprofen intravenously (Rimadyl®, Pfizer
AG, Zürich, Switzerland) during 4 days.
The transcutaneously treated groups were subjected to
18 applications, 3 applications per week at 15 minutes
each for a total of six weeks (Figure 1). For drug delivery,
the applicator was held in a distance of approximately
1 cm from the skin in an angle of 90° degrees. The areas
of skin around the stifle joint were treated in an area of
approximately 10 cm2 on the medial side of the limb,
medial to the surgical wound and an equally sized area
lateral to the surgical wound.
For the measurements of carprofen concentration pre-
sented here, 2 sheep from groups 3 (VECA), 4 (VECHCA)
and 6 (CA) were included. The first transcutaneous treat-
ment was performed one day prior to surgery (Day 0).
The day of surgery was termed day 1. The transcutaneous
treatments were performed on days 0, 3, 5, 8, 10, 12, 15,
17, 19, 22, 24, 26, 29, 31, 33, 36, 38 and 40. After the first
two transcutaneous treatments (day 0 and 3) the blood
samples were taken from groups 3 and 4 at −5, 15, 20, 30,
60 minutes and 2, 3, 6 and 18 hours in relation to the
application. In addition, blood samples were taken on days
5, 12, 19, 26, 33 and 40, always 6 hours after the transcuta-
neous application.
Synovial fluid was collected during surgery and after-
wards once a week during 6 weeks using ultrasound guid-
ance (Figure 2). For this purpose the sheep were sedated
with Medetomidine (20ug/kg BW, Dorbene, Dr. E. Graeub
AG, Switzerland). They were placed on their hindquarters
Figure 2 US performance for synovial fluid sample taking. A. Positioning of sheep. B. Setting how synovial fluid was taken. C. Position of the
sheep's limb to expose the medial articular pocket.
Sidler et al. BMC Veterinary Research 2014, 10:268 Page 3 of 9
http://www.biomedcentral.com/1746-6148/10/268
and positioned in a more lateral position in order to
expose the medial articular pocket of the limb that under-
went surgery.
Additionally, blood samples were taken for comparison.
The blood samples from the intravenously treated group 6
(CA) were taken on day 1, 2, 3, 4, and 5 at time points −5,
10, and 60 minutes and 3, 6 and 12 hours after the iv.
carprofen administration. Two further blood samples were
taken on day 8 and 12.
All blood samples were taken from the jugular vein.
The first 4 ml of blood was discarded and the remaining
6 ml of blood was filled into a lithium heparin tube and
centrifuged for 20 minutes at 1500 U/min. The resulting
plasma was transferred into labelled sterile 1.5 ml
eppendorf tubes and stored at −20°C for batch analysis.
Synovial fluid samples were obtained using a 5 ml syringe
(Braun, Omnifix®) and a 18 G needle (Terumo®, Terumo
Europe N.V., Belgium) and were stored in pre-labelled
sterile 1.5 ml eppendorf tubes. Each sample was wrapped
in aluminium foil and stored at −20°C for later batch
analysis (Interlabor Belp AG, Belp, Switzerland). The
carprofen concentrations were measured using high per-
formance liquid chromatography (HPLC) in connection
with Tandem - Mass Spectroscopy (HPLC-MS/MS). The
liquid chromatography (Dionex UltiMate 300, Software
Dionex Chromatography MS Link Vers. 2.7.0.2251) was
used to separate the mixture of compounds into single
components and the Mass-Spectroscopy (Triple Quad-
rupol Sciex API 4000, Software Analyst Vers. 1.5.1) to
identify and quantify the components.
Results
Group 3 (VECA, animals 5203/04)
The first measurable carprofen values after the initial
transcutaneous application were obtained at 30 min and
60 min in animals 5203 and 5204, respectively (<2 ng/ml)
(Table 1). The highest values after the first application
were measured after 18 hours (5203) and 20 hours (5204),
respectively. Just before the second application (after
72 h), the blood concentration dropped to 49% (5203) and
67% (5204), respectively (Figure 3A).
After the second application, the blood values rose at
one hour in both animals and the highest concentration
was measured again after 18 hours in both animals.
The peak concentration after the second application
was 2.6- (5203) and 5.7- (5204) fold higher than the peak
concentration after the first application (Figure 3B). The
highest plasma level was measured in the 6th application
week in both animals (553 ng/ml in 5203 and 695 ng/ml
in 5204). After completion of the last application (week 6),
the carprofen concentration in the plasma dropped. Six
days after the last application the measured plasma level
was not more than 18% (5203) and 24% (5204) of the
highest value in week 6 (Figure 3C).
Synovial samples
An overview of the synovial fluid measurements is pro-
vided in Table 2. The highest carprofen concentration in
the synovial fluid was measured in week 6 and correlated
with the highest carprofen plasma concentration. We
measured values of 327 ng/ml (5203) and 281 ng/ml
(5204), respectively (Figure 3E).
The synovial carprofen concentration was on average
48% (5203) and 49% (5204) lower than the simultaneously
taken blood samples.
Group 4 (VECHCA animals 5211/12)
Plasma samples
The highest concentrations after the first application were
measured at 18 hours (5211) and 20 hours (5212), simi-
larly to Group 3 (Table 3). After 72 hours, the carprofen
concentration in the plasma dropped to 42% (5211) and
67% (5212) of the earlier measured peak plasma level
(Figure 1A). After the second application, the highest
Table 1 Carprofen concentrations of plasma samples
Group 3 (VECA)
Timepoint 5203 (VECA)
c(ng/ml)
5204 (VECA)
c(ng/ml)
Day 0 (1 day prior surgery) - -
15 min. after 1st application (day 0) - -
20 min. after 1st application (day 0) - -
30 min. after 1st application (day 0) <2.0 -
1 h after 1st application (day 0) 2.6 <2.0
2 h after 1st application (day 0) 5.5 4.1
3 h after 1st application (day 0) 7.2 7.7
6 h after 1st application (day 0) 19.1 16.8
18 h after 1st application (day 1) 72.0 54.1
Intra OP (day 1) 61.0 57.1
5 min. prior to 2nd application (day 3) 35.4 38.0
15 min. after 2nd application (day 3) 34.3 34.6
20 min. after 2nd application (day 3) 33.8 35.4
30 min. after 2nd application (day 3) 34.8 35.5
1 h after 2nd application (day 3) 33.8 36.2
2 h after 2nd application (day 3) 41.2 42.1
3 h after 2nd application (day 3) 46.8 46.4
6 h after 2nd application (day 3) 104 105
18 h after 2nd application (day 4) 187 325
6 h after application (week 1) 416 456
6 h after application (week 2) 419 347
6 h after application (week 3) 402 479
6 h after application (week 4) 301 376
6 h after application (week 5) 203 412
6 h after application (week 6) 343 675
1 week after the last application (week 7) 63.4 163
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concentration was measured in plasma of both animals at
18 hours. The peak concentration after the second appli-
cation was 1.7- (5211) and 4- (5212) times higher than the
peak concentration after the first application (Figure 3B).
The highest concentration of animal 5211 was measured
in the 6th application week (1620 ng/ml). The highest
concentration of animal 5212 was measured in the 3rd
application week (635 ng/ml).
At 6 days after the last application the plasma concen-
tration dropped to 36% (5211) and 37% (5212) of the
peak values measured before (Figure 3C).
Synovial samples
An overview of the measurements of the synovial fluid
is provided in Table 4. The highest synovial concentra-
tion (1350 ng/ml) was measured simultaneously with
the highest plasma concentration in the 6th appli-
cation week in animal 5211. In animal 5212 the high-
est synovial concentration was measured in week 4
(418 ng/ml).
The synovial concentration in week 7 reached 21% (5211)
and 3% (5212) of the mean value of the afore measured
peak concentrations (Figure 3E).
Figure 3 Carprofen plasma and synovial fluid levels. Overview of the blood plasma (A-C) and synovial fluid (E) carprofen levels of the
transcutaneous treated groups 3 & 4 and the blood plasma levels of the intravenous treated group 6 (D).
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All synovial samples had lower carprofen concentrations
than the plasma samples. The synovial samples reached
59% (5211) and 58% (5212) of the simultaneously taken
plasma samples.
Group 6 (CA animals 5202/17)
Plasma samples
The intravenously treated animals showed an interval peak
plasma concentration, as described in a previous study [17]
in sheep. The concentration was highest 10 minutes after
the iv. application and lowest shortly before the next appli-
cation (Table 5). The plasma concentration dropped after
completion of the treatment. Nevertheless, after 12 days,
the plasma level still presented with concentrations of
500 ng/ml (5202) and 2115 ng/ml (5217), respectively
(Figure 3D).
Comparisons between groups 3, 4 and 6
The highest concentration of the intravenously treated
group was measured at 10 minutes after the first applica-
tion, whereas the highest concentration of the transcuta-
neously treated groups was measured after 18 – 20 hours.
After the iv. administration of carprofen, the plasma
concentration reached an average of 38.7 μg/ml whereas
the plasma level of the transcutaneously treated group
recorded an average of 139.95 ng/ml. Therefore, the
plasma concentration of carprofen in the transcutaneously
treated animals (groups 3 VECA and 4 VECHCA)
remained almost 300-fold lower than in the intravenously
treated group 6 (CA). It should be noted however, that the
overall carprofen dose was greater following intravenous
injection as compared to transcutaneous. The ratio of
measured plasma concentration to totally administered
dose was as follows: in group 3, 1:80 (animal 5203) and
Table 2 Carprofen concentrations of synovial fluid
samples Group 3 (VECA)
Timepoint 5203 (VECA)
c(ng/ml)
5204 (VECA)
c(ng/ml)
Intra OP (day 1) 25.3 13.4
Week 1 (taken under ultrasound control) 77.8 209
Week 2 (taken under ultrasound control) 293 274
Week 3 (taken under ultrasound control) 65.6 239
Week 4 (taken under ultrasound control) 195 178
Week 5 (taken under ultrasound control) 61.3 194
Week 6 (taken under ultrasound control) 327 281
Week 7 (1 week after the last application) 23.6 26.4
Table 3 Carprofen concentrations of plasma samples
Group 4 (VECHCA)
Timepoint 5211 (VECHCA)
c(ng/ml)
5212 (VECHCA)
c(ng/ml)
Day 0 (1 day prior surgery) 33.1 17.4
15 min. after 1st application (day 0) 33.0 18.0
20 min. after 1st application (day 0) 69.2 16.6
30 min. after 1st application (day 0) 35.7 12.1
1 h after 1st application (day 0) 40.5 13.7
2 h after 1st application (day 0) 76.4 14.9
3 h after 1st application (day 0) 120 20.0
6 h after 1st application (day 0) 178 28.4
18 h after 1st application (day 1) 342 81.9
Intra OP (day 1) 297 88.7
5 min. prior to 2nd application (day 3) 145 59.6
15 min. after 2nd application (day 3) 114 52.3
20 min. after 2nd application (day 3) 108 53.1
30 min. after 2nd application (day 3) 134 57.8
1 h after 2nd application (day 3) 135 58.9
2 h after 2nd application (day 3) 188 65.4
3 h after 2nd application (day 3) 269 85.8
6 h after 2nd application (day 3) 360 176
18 h after 2nd application (day 4) 572 353
6 h after application (week 1) 849 448
6 h after application (week 2) 882 365
6 h after application (week 3) 959 490
6 h after application (week 4) 949 525
6 h after application (week 5) 1327 580
6 h after application (week 6) 1347 391
1 week after the last
application (week 7)
486 146
Table 4 Carprofen concentrations of synovial fluid
samples Group 4 (VECHCA)
Timepoint 5211 (VECHCA)
c(ng/ml)
5212 (VECHCA)
c(ng/ml)
Intra OP (day 1) 134 78
Week 1 (taken under
ultrasound control)
394 229
Week 2 (taken under
ultrasound control)
845 352
Week 3 (taken under
ultrasound control)
461 417
Week 4 (taken under
ultrasound control)
398 418
Week 5 (taken under
ultrasound control)
501 288
Week 6 (taken under
ultrasound control)
1350 213
Week 7 (1 week after
the last application)
165 13.4
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1:85 (animal 5204); group 4, 1:17 (animal 5211) and 1:65
(animal 5212).
The volume of distribution was low in the iv. group 6
(0.09 – 0.11 l/kg) shortly after the injection, but in-
creased until the next injection. This was in contrast to
the transcutaneously treated group, where the highest
volumes of distribution were calculated shortly after the
application (16.86 – 125 l/kg), and reduced over time.
Discussion
In this study, we concentrate on reporting of the results
of the carprofen receiving Groups 3 (VECA) and 4
(VECHCA) and show that the Vetdrop® System allows
for transcutaneous delivery of carprofen. The results of
the other 3 Groups are not addressed because they did
not receive carprofen, but their results are reported
elsewhere (Dissertation Nathalie Fouché, 2012).
In Groups 3 (VECA) and 4 (VECHCA) detectable car-
profen concentrations were found in synovial fluid of the
stifle as well as in the systemic blood circulation, although
systemic concentrations were lower compared to control
animals treated with carprofen intravenously.
The concentration of carprofen and some pharmacoki-
netic values could be determined, but direct comparisons
with the control group (iv. application) were not consid-
ered totally appropriate. Pharmacokinetic calculations are
based on the assumption that drugs are administered
into a central compartment and subsequently distrib-
uted into peripheral compartments. This sequence is
inverted with transcutaneous administrations and as
such, pharmacokinetic algorithms may not fully apply
in the case of transcutaneous delivery. Nevertheless, the
standard pharmacokinetic formulas may help to interpret
the data.
Factors, such as anatomical site, age, sex and skin disease
influence the consistency of the epidermis and conse-
quently the ability of substances to penetrate the skin
barrier. Furthermore, drug delivery is also dependent
on the pathways of skin permeation. Generally, it is
considered that drug components can either pass the
epidermis through a combination of transport routes
including appendages or via a trans- or an intracellular
route, and that the relative contribution of each of
these is dependent on the physicochemical properties
of the formulation and the properties of the skin.
Carprofen is a commonly used NSAID in veterinary
medicine and was thus considered an ideal study mater-
ial for the purposes of the current study. It has strong
analgesic, antipyretic and antiphlogistic effects [17-19],
although the exact mechanism of action of carprofen is
not yet clear [20]. In vitro assays performed, using canine
and equine chondrocytes demonstrated carprofen as
having an inhibitory effect on prostaglandin-E2-synthesis
[15,21].
In our study, both Groups 3 (VECA) and 4 (VECHCA)
reached the peak plasma level (57.1 – 342 ng/ml) between
18 – 20 hours after the first application.
In a transdermally administered fentanyl patch (2.05 μg/
kg/h) study in 21 sheep, Ahern et al. [22] observed peak
plasma concentrations between 4 and 24 h (0.62 –
2.73 ng/ml). Although the peak plasma concentration
levels in the current study were wide ranging, they were
always reached.
After the 2nd application, peak plasma level rose up
to 5.7-fold higher (up to 572 ng/ml) as compared to the
initial application. This indicated that carprofen accu-
mulated in the body. Nevertheless, the measured plasma
concentration was consistently lower as compared to
the intravenous administration of carprofen (up to
42 μg/ml, 10 min after 3rd application, = 48 h after the
1st application).
Table 5 Carprofen concentration measurements of
plasma samples Group 6 (CA)
Timepoint 5202 (CA)
c(ng/ml)
5217 (CA)
c(ng/ml)
Day 1 (day of surgery) 0.0 0.0
10 min. after 1st injection (day 1) 37500 39950
1 h after 1st injection (day 1) 29400 34217
2 h after 1st injection (day 1) 24400 27300
3 h after 1st injection (day 1) 23000 25917
12 h after 1st injection (day 1) 18200 23317
5 min prior to 2nd injection (day 2) 14100 21965
10 min after 2nd injection (day 2) 39100 43583
1 h after 2nd injection (day 2) 16000 38217
2 h after 2nd injection (day 2) 31400 37068
3 h after 2nd injection (day 2) 29200 35967
12 h after 2nd injection (day 2) 25900 31900
5 min prior to 3rd injection (day 3) 20000 25550
10 min after 3rd injection (day 3) 39700 42083
1 h after 3rd injection (day 3) 36100 40150
2 h after 3rd injection (day 3) 31900 36400
3 h after 3rd injection (day 3) 30100 34317
12 h after 3rd injection (day 3) 26200 31650
5 min prior to 4th injection (day 4) 27417
10 min after 4th injection (day 4) 41300
1 h after 4th injection (day 4) 39267
2 h after 4th injection (day 4) 37433
3 h after 4th injection (day 4) 36917
12 h after 4th injection (day 4) 32950
1 day after the last injection (day 5) 16200 23150
3 days after the last injection (day 8) 5200 6917
1 week after the last injection (day 12) 500 2115
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The carprofen concentration in the synovial fluid of
group 3 (VECA) reached between 48 – 49% of the carpro-
fen plasma level and in group 4 (VECHCA) 58 -59%.
Group 4 (VECHCA) accumulated noticeably more carpro-
fen in the synovial fluid as compared to group 3 (VECA).
This effect may have been related to the additional chito-
oligosaccharids in group 4 (VECHCA).
Analysing transdermally administered pharmaceutical
agents raises the question as to whether the active ingre-
dients reach their target location through direct penetra-
tion of the target tissue or through redistribution from
systemic blood circulation Mills et al. [23] stated that
topically applied NSAIDs can penetrate into deeper
tissues and into the synovial fluid, and that local blood
redistribution is contributing to this effect. They suggested
that certain NSAIDs might increase the local blood flow
and assist in transporting the applied drugs deeper into
the tissue prior to their distribution into the systemic
blood circulation. Indeed, Singh and Roberts [24] demon-
strated that local tissue penetration of NSAIDs was pos-
sible up to a depth of 3 – 4 mm. However, Radermacher
et al. [25] observed that the distribution of topically
applied diclofenac into the synovial fluid was achieved
through the blood supply and that direct penetration was
minimal.
Conclusions
In this preliminary study we showed that the measured
synovial concentration was always lower than the plasma
concentration. Nevertheless, carprofen reached concentra-
tions in the joint that are considered as being admissible
for long-term therapy. Whether carprofen is transported
directly into the joint or redistributed after systemic
circulation is not yet clear and further investigations are
needed. Therefore, in a main study a larger pharmacoki-
netic analysis needs to be set up.
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